Article info

Original research
Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer

Authors

  1. Correspondence to Dr Lawrence G. Lum; Lgl4f{at}hscmail.mcc.virginia.edu; Dr Archana Thakur; AT2Fx{at}hscmail.mcc.virginia.edu
View Full Text

Citation

Lum LG, Al-Kadhimi Z, Deol A, et al
Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer

Publication history

  • Accepted May 8, 2021
  • First published June 11, 2021.
Online issue publication 
February 24, 2022
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.